Recent research on the dynamic behavior of the carnitine carrier underscores the importance of pathway led by CAC and carnitine-dependent acyltransferases in cancer cell metabolism, suggesting that modulation of this system could become a novel strategy for cancer treatment, aiming at reprogramming metabolism in mitochondrial diseases and cancer, providing a multifaceted approach to treatment development. Here, SLC25A20 is linked to cancer.